Bioactive  ||| S:0 E:10 ||| JJ
spirostane  ||| S:10 E:21 ||| JJ
glycosides  ||| S:21 E:32 ||| NN
from  ||| S:32 E:37 ||| IN
Tacca  ||| S:37 E:43 ||| NNP
plantaginea  ||| S:43 E:55 ||| VBD
Eight  ||| S:55 E:61 ||| CD
new  ||| S:61 E:65 ||| JJ
spirostane  ||| S:65 E:76 ||| JJ
glycosides ||| S:76 E:86 ||| NN
,  ||| S:86 E:88 ||| ,
taccaosides  ||| S:88 E:100 ||| JJ
E-L  ||| S:100 E:104 ||| NN
( ||| S:104 E:105 ||| -LRB-
2-7 ||| S:105 E:108 ||| NNP
,  ||| S:108 E:110 ||| ,
11 ||| S:110 E:112 ||| CD
,  ||| S:112 E:114 ||| ,
and  ||| S:114 E:118 ||| CC
14 ||| S:118 E:120 ||| CD
) ||| S:120 E:121 ||| -RRB-
,  ||| S:121 E:123 ||| ,
along  ||| S:123 E:129 ||| RB
with  ||| S:129 E:134 ||| IN
7  ||| S:134 E:136 ||| CD
known  ||| S:136 E:142 ||| VBN
spirostane  ||| S:142 E:153 ||| JJ
glycosides  ||| S:153 E:164 ||| NN
were  ||| S:164 E:169 ||| VBD
isolated  ||| S:169 E:178 ||| VBN
from  ||| S:178 E:183 ||| IN
the  ||| S:183 E:187 ||| DT
extract  ||| S:187 E:195 ||| NN
of  ||| S:195 E:198 ||| IN
the  ||| S:198 E:202 ||| DT
whole  ||| S:202 E:208 ||| JJ
plants  ||| S:208 E:215 ||| NNS
of  ||| S:215 E:218 ||| IN
Tacca  ||| S:218 E:224 ||| NNP
plantaginea  ||| S:224 E:236 ||| NNS
( ||| S:236 E:237 ||| -LRB-
Hance ||| S:237 E:242 ||| NNP
)  ||| S:242 E:244 ||| -RRB-
Drenth ||| S:244 E:250 ||| NNP
.  ||| S:250 E:252 ||| .
Their  ||| S:252 E:258 ||| PRP$
structures  ||| S:258 E:269 ||| NNS
were  ||| S:269 E:274 ||| VBD
established  ||| S:274 E:286 ||| VBN
on  ||| S:286 E:289 ||| IN
the  ||| S:289 E:293 ||| DT
basis  ||| S:293 E:299 ||| NN
of  ||| S:299 E:302 ||| IN
physical  ||| S:302 E:311 ||| JJ
data ||| S:311 E:315 ||| NNS
,  ||| S:315 E:317 ||| ,
spectroscopic  ||| S:317 E:331 ||| JJ
analysis  ||| S:331 E:340 ||| NN
( ||| S:340 E:341 ||| -LRB-
MS ||| S:341 E:343 ||| NNP
,  ||| S:343 E:345 ||| ,
1D  ||| S:345 E:348 ||| NNP
and  ||| S:348 E:352 ||| CC
2D  ||| S:352 E:355 ||| NNP
NMR ||| S:355 E:358 ||| NNP
) ||| S:358 E:359 ||| -RRB-
,  ||| S:359 E:361 ||| ,
and  ||| S:361 E:365 ||| CC
chemical  ||| S:365 E:374 ||| JJ
methods ||| S:374 E:381 ||| NNS
.  ||| S:381 E:383 ||| .
The  ||| S:383 E:387 ||| DT
cytotoxicities  ||| S:387 E:402 ||| NN
of  ||| S:402 E:405 ||| IN
the  ||| S:405 E:409 ||| DT
isolates  ||| S:409 E:418 ||| NN
were  ||| S:418 E:423 ||| VBD
evaluated  ||| S:423 E:433 ||| VBN
in  ||| S:433 E:436 ||| IN
vitro  ||| S:436 E:442 ||| NN
against  ||| S:442 E:450 ||| IN
two  ||| S:450 E:454 ||| CD
human  ||| S:454 E:460 ||| JJ
cancer  ||| S:460 E:467 ||| NN
cell  ||| S:467 E:472 ||| NN
lines  ||| S:472 E:478 ||| NNS
( ||| S:478 E:479 ||| -LRB-
HEK293  ||| S:479 E:486 ||| NNP
and  ||| S:486 E:490 ||| CC
HepG2 ||| S:490 E:495 ||| CD
) ||| S:495 E:496 ||| -RRB-
.  ||| S:496 E:498 ||| .
The  ||| S:498 E:502 ||| DT
results  ||| S:502 E:510 ||| NNS
showed  ||| S:510 E:517 ||| VBD
that  ||| S:517 E:522 ||| DT
compound  ||| S:522 E:531 ||| NN
1  ||| S:531 E:533 ||| CD
had  ||| S:533 E:537 ||| VBD
the  ||| S:537 E:541 ||| DT
strongest  ||| S:541 E:551 ||| JJS
cytotoxic  ||| S:551 E:561 ||| JJ
activity  ||| S:561 E:570 ||| NN
with  ||| S:570 E:575 ||| IN
IC50  ||| S:575 E:580 ||| CD
values  ||| S:580 E:587 ||| NNS
of  ||| S:587 E:590 ||| IN
1.7μM  ||| S:590 E:596 ||| NNP
and  ||| S:596 E:600 ||| CC
1.2μM  ||| S:600 E:606 ||| CD
against  ||| S:606 E:614 ||| IN
the  ||| S:614 E:618 ||| DT
two  ||| S:618 E:622 ||| CD
cancer  ||| S:622 E:629 ||| NN
cell  ||| S:629 E:634 ||| NN
lines ||| S:634 E:639 ||| NNS
,  ||| S:639 E:641 ||| ,
respectively ||| S:641 E:653 ||| RB
.  ||| S:653 E:655 ||| .
Furthermore ||| S:655 E:666 ||| RB
,  ||| S:666 E:668 ||| ,
the  ||| S:668 E:672 ||| DT
spirostane  ||| S:672 E:683 ||| JJ
glycosides  ||| S:683 E:694 ||| NN
with  ||| S:694 E:699 ||| IN
17α-hydroxyl  ||| S:699 E:712 ||| CD
group  ||| S:712 E:718 ||| NN
at  ||| S:718 E:721 ||| IN
their  ||| S:721 E:727 ||| PRP$
aglycones  ||| S:727 E:737 ||| NNS
( ||| S:737 E:738 ||| -LRB-
10 ||| S:738 E:740 ||| CD
,  ||| S:740 E:742 ||| ,
12 ||| S:742 E:744 ||| CD
,  ||| S:744 E:746 ||| ,
and  ||| S:746 E:750 ||| CC
15 ||| S:750 E:752 ||| CD
)  ||| S:752 E:754 ||| -RRB-
were  ||| S:754 E:759 ||| VBD
tested  ||| S:759 E:766 ||| VBN
for  ||| S:766 E:770 ||| IN
the  ||| S:770 E:774 ||| DT
induced  ||| S:774 E:782 ||| JJ
platelet  ||| S:782 E:791 ||| JJ
aggregation  ||| S:791 E:803 ||| JJ
activity ||| S:803 E:811 ||| NN
.  ||| S:811 E:813 ||| .
